株式会社ジーエヌアイグループ 2022年12月期 連結決算概要

This document outlines the consolidated financial results of GNI Group Ltd. for the fiscal year ending December 2022. The company emphasizes its global revenue sources and is focusing on expanding its operations in the U.S. and China. Notably, it highlights its innovative drug discovery platform and the growth of its medical device business, with a 26% increase in R&D investment compared to the previous year. The document also emphasizes the company's commitment to environmental, social, and governance (ESG) initiatives, including corporate citizenship activities and the promotion of diversity. Overall, it presents a strategy aimed at sustainable growth and improved profitability.